Hyperbaric oxygen treatment (HBO) is a treatment that is now being experimentally studied in adult patients with severe traumatic brain injuries (TBI). Hyperbaric oxygen treatment is a specialized way, using a pressure chamber, to dramatically increase the amount of oxygen delivered to body tissues.
Newly published research has found familiar music can elicit an extended emotional response in patients with Alzheimer’s-type dementia. The findings from this potential new approach were featured in the Journal of Alzheimer’s Disease.
Florin Despa says that a major scientific goal is to understand whether the same factors that are involved in age-related metabolic disorders such as type-2 diabetes may also play a role in the development and progression of cognitive decline and dementia.
Dr. Peter Nelson, of the University of Kentucky’s Sanders-Brown Center on Aging, has spent the last 15 years in the Commonwealth helping to lead the fight against Alzheimer’s and dementia inducing brain disease.
A $2.9 million grant from the NIH is supporting a multidisciplinary team of UK researchers in continuing their work to find therapeutic strategies to resolve neurovascular inflammation and repair blood-brain barrier dysfunction in epilepsy.
In the sessions for both the scientific and community audience, attendees will have the opportunity to hear clinicians and researchers from UK and other institutions share current findings, trends, and latest updates on dementia and aging disorders.
Butterfield is among the top 0.007% of scholars worldwide based on authorship of Alzheimer’s-related publications indexed in the PubMed database for the past 10 years. He ranks tenth out of nearly 150,000 scholars worldwide and sixth in the U.S.
In addition to opening the door to developing blockers of odors, McClintock says this work will help researchers understand why formulating fragrances and flavors with specific properties is so difficult. “Ergo, the oft-used phrase 'the art of perfumery.' Eventually, we will turn this art into science.”
Selenica says their study is the first to provide a novel pathway and identify potential therapeutic targets for TDP-43 proteinopathies – especially in Alzheimer’s disease and the newly characterized form of dementia known as LATE.